ASCO 2021

Area: Oncology

Location: Online, Virtual

Date: June 4 to June 8


Search in Scientific Content:
Date
Filters:
Expanded e
10:42

Expanded efficacy and safety data from CheckMate 649

Presenter: Markus Moehler
Oncology
Current st
8:18

Current state of frontline immunotherapy options in the treatment of NSCLC

Presenter: Federico Cappuzzo
Oncology
Clinical d
9:37

Clinical decision making in the treatment of melanoma

Presenter: Paolo A. Ascierto
Oncology
State of t
7:15

State of the art treatment of prostate cancer

Presenter: Oliver Sartor
Oncology
State of t
5:21

State of the art treatment of breast cancer

Presenter: Virginia G. Kaklamani
Oncology
State of t
17:01

State of the art treatment of multiple myeloma

Presenter: Andrzej Jakubowiak
Oncology
Current st
13:02

Current state of immunotherapy options in the treatment of RCC

Presenter: Camillo Porta
Oncology
Effect of
12:51

Effect of first-line pembrolizumab treatment in individuals with advanced non-small cell lung cancer and poor performance status.

Presenter: Rajwanth Veluswamy
Oncology
Current st
11:17

Current state of immunotherapy options in the treatment of melanoma

Presenter: Jeffrey Weber
Oncology
State of t
17:17

State of the art treatment of breast cancer

Presenter: Jane Lowe Meisel
Oncology
Response a
6:58

Response and survival results up to five years from the KEYNOTE-052 phase 2 study

Presenter: Arjun Vasant Balar
Oncology
Expanded e
6:07

Expanded efficacy and safety analyses from CheckMate 577

Presenter: Ronan Joseph Kelly
Oncology
IMpower010
5:36

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer

Presenter: Heather A. Wakelee
Oncology
Relatlimab
6:55

Relatlimab plus nivolumab versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047

Presenter: Evan J. Lipson
Oncology
ODENZA: A
4:28

ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).

Presenter: Emeline Colomba
Oncology

ESMO 2021

2021-09-17 - 2021-09-21
Online, Virtual

St. Gallen BCC 2021

2021-03-17 - 2021-03-21
Online, Virtual

SABCS 2020

2020-12-08 - 2020-12-11
Online, Virtual

ESMO 2020

2020-09-19 - 2020-09-21
Online, Virtual

ASCO 2020

2020-05-29 - 2020-05-31
Online, Virtual

ESMO 2019

2019-09-27 - 2019-10-01
Barcelona, Spain

ASCO 2019

2019-05-31 - 2019-06-04
Chicago, United States

EADO 2019

2019-04-24 - 2019-04-27
Paris, France

BCC 2019

2019-03-20 - 2018-03-23
Vienna, Austria